 |
|
|
| |
Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients
|
| |
| |
Reported by Jules Levin
Meeting of the European Association for the Study of the Liver. Amsterdam, The Netherlands, April 24-28, 2013
Everson GT,1 Sims KD,2 Rodriguez-Torres M,3 Hezode C,4 Lawitz E,5 Bourliere M,6 Loustaud-Ratti V,7 Rustgi V,8 Schwartz H,9 Tatum H,10 Marcellin P,11
Pol S,12 Thuluvath PJ,13 Eley T,2 Wang X,2 Huang S-P,14 McPhee F,15 Wind-Rotolo M,14 Chung E,2 Pasquinelli C,2 Grasela DM,2 Gardiner DF2
1University of Colorado Denver, Aurora, CO, USA; 2Bristol-Myers Squibb, Hopewell, NJ, USA; 3Fundacion de Investigacion, San Juan, Puerto Rico; 4CHU Henri Mondor, Service d'Hepato-Gastroenterologie, Creteil, France; 5Alamo Medical Research, San Antonio, TX, USA;
6Hopital Saint Joseph, Service d'Hepato-Gastroenterologie, Marseille, France; 7University Hospital of Limoges, Limoges, France; 8Metropolitan Research, Arlington, VA, USA; 9Miami Research Associates, South Miami, FL, USA; 10Options Health Research, Tulsa, OK, USA;
11Hopital Beaujon, Clichy, France; 12Universite Paris Descartes, INSERM U1610 and Liver Unit, Hopital Cochin, Paris, France; 13Mercy Medical Center, Baltimore, MD, USA; 14Bristol-Myers Squibb, Princeton, NJ, USA; 15Bristol-Myers Squibb, Wallingford, CT, USA
|
| |
|
|
|
|
|
